Antitumor mechanism of metformin via adenosine monophosphate-activated protein kinase (AMPK) activation

Chinese Journal of Lung Cancer

Volumn 16, Issue 8, 2013, Pages 427-432

  Chen, Zhaoyu ^a   Wang, Liantang ^b   Chen, Yanyang ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adenosine monophosphate activated protein kinase (AMPK); Antitumor mechanism; Cell cycle arrest; Metabolism; Metformin; Oxidative stress; Transformation of cancer tumor stem cells

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CELL TRANSFORMATION; METABOLISM; MORBIDITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; CELL CYCLE; ENZYME ACTIVATION; HUMANS; METFORMIN; NEOPLASTIC STEM CELLS;

EID: 84881571045     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2013.08.07     Document Type: Article

References (36)

1. Wiernsperger NF, Bailey CJ. The antihy perglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs, 1999, 58(Suppl 1): 31-39, 75-82.
2. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 330(7503): 1304-1305.
3. Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol, 2013, 705(1-3): 96-108.
4. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila), 2010, 3(9): 1066-1076.
5. Zhu Z, Jiang W, Thompson MD, et al. Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog, 2011, 10: 17.
6. Zhang ZJ, Zheng ZJ, Shi R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2012, 97(7): 2347-2353.
7. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol, 2007, 8(10): 774-785.
8. Carling D, Sanders MJ, Woods A. The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes (Lond), 2008, 32(Suppl 4): S55-S59.
9. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem, 2000, 275(1): 223-228.
10. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med, 2011, 9: 33.
11. Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 2002, 51(8): 2420-2425.
12. Zhang Y, Wang Y, Bao C, et al. Metformin interacts with AMPK through binding to gamma subunit. Mol Cell Biochem, 2012, 368(1-2): 69-76.
13. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 2010, 6(3): 457-470.
14. Xiao X, He Q, Lu C, et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol, 2012, 127(1): 249-255.
15. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res, 2007, 100(3): 328-341.
16. Rajendran R, Garva R, Ashour H, et al. Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer. Int J Oncol, 2013, 42(6): 1961-1972.
17. Hao LS, Zhang ZR, Wu XR. Advance in bioenergetic metabolic mechanisms of cancer cell. Zhongguo Pu Wai Ji Chu Yu Lin Chuang Za Zhi, 2010, 17(1): 97-101.
18. Algire C, Moiseeva O, Deschenes-Simard X, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila), 2012, 5(4): 536-543.
19. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J, 2009, 417(1): 1-13.
20. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle, 2011, 10(23): 4047-4064.
21. Lin CC, Yeh HH, Huang WL, et al. Metformin enhances cisplatin cytotoxicity by suppressing Stat3 activity independently of the LKB1- AMPK pathway. Am J Respir Cell Mol Biol, 2013 Mar 22. [Epub ahead of print]
22. Lee JH, Kim JH, Kim JS, et al. AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumininduced epithelial-mesenchymal transition. Am J Physiol Renal Physiol, 2013, 304(6): 686-697.
23. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 2012, 485(7400): 661-665.
24. Luo Q, Hu D, Hu S, et al. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer, 2012, 12: 517.
25. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal, 2008, 3: 18.
26. Zhao L, Wen ZH, Jia CH, et al. Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells. Anat Rec (Hoboken), 2011, 294(8): 1337-1343.
27. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut, 2013, 62(4): 606-615.
28. Ben SI, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008, 27(25): 3576-3586.
29. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. PNAS, 2013, 110(3): 972-977.
30. Tornatore L, Thotakura AK, Bennett J, et al. The nuclear factor kappa B signaling pathway: integrating metabolism with inf lammation. Trends Cell Biol, 2012, 22(11): 557-566.
31. Ginn-Pease ME, Whisler RL. Optimal NF kappa B medi ated transcriptional responses in Jurkat T cells exposed to oxidative stress are dependent on intracellular glutathione and costimulatory signals. Biochem Biophys Res Commun, 1996, 226(3): 695-702.
32. Lee YC, Lee KS, Park SJ, et al. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazol idine-4 -carbox yl ic acid. FASEB J, 2004, 18(15): 1917-1919.
33. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA, and IL6 links inf lammation to cell transformation. Cell, 2009, 139(4): 693-706.
34. Song EW. Research progress of solid tumor stem cells. Zhongshan Da Xue Xue Bao (Med Sci), 2010, 31(2): 172-178.
35. Rattan R, Graham RP, Maguire JL, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 2011, 13(5): 483-491.
36. Ji G, Zhang Y, Yang Q, et al. Genistein suppresses LPS-induced inflammatory response through inhibiting NF-κB following AMP kinase activation in RAW 264.7 macrophages. PLoS One, 2012, 7(12): e53101.